FDA harps on risks of Pfizer’s tofacitinib as panel looms

FDA staffers drew attention to safety risks associated with Pfizer's blockbuster contender tofacitinib in briefing documents. The agency's concerns come days before a panel of non-FDA experts delves i…
Read the full story: News